These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28932823)

  • 1. ISN Forefronts Symposium 2015: Nuclear Receptors and Diabetic Nephropathy.
    Zheng B; Chen L; Gonzalez FJ
    Kidney Int Rep; 2016 Sep; 1(3):177-188. PubMed ID: 28932823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear hormone receptors as therapeutic targets.
    Levi M; Wang X; Choudhury D
    Contrib Nephrol; 2011; 170():209-216. PubMed ID: 21659773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Management of Diabetic Nephropathy in Western Countries.
    Satirapoj B; Adler SG
    Kidney Dis (Basel); 2015 May; 1(1):61-70. PubMed ID: 27536666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear receptors in renal disease.
    Levi M
    Biochim Biophys Acta; 2011 Aug; 1812(8):1061-7. PubMed ID: 21511032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear hormone receptors in diabetic nephropathy.
    Wang XX; Jiang T; Levi M
    Nat Rev Nephrol; 2010 Jun; 6(6):342-51. PubMed ID: 20421884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
    Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
    Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of diabetic nephropathy: Recent progress and future perspective.
    Ahmad J
    Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence and Management of Diabetic Nephropathy in Asia.
    Tomino Y; Gohda T
    Kidney Dis (Basel); 2015 May; 1(1):52-60. PubMed ID: 27536665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic nephropathy: An update on pathogenesis and drug development.
    A/L B Vasanth Rao VR; Tan SH; Candasamy M; Bhattamisra SK
    Diabetes Metab Syndr; 2019; 13(1):754-762. PubMed ID: 30641802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment.
    Samsu N
    Biomed Res Int; 2021; 2021():1497449. PubMed ID: 34307650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Treatment Effectiveness Evaluation for Slowing the Progression of Diabetic Nephropathy During Stage 4 Chronic Kidney Disease.
    Yu T; Jiang S; Yang Y; Fang J; Zou G; Gao H; Zhuo L; Li W
    Diabetes Ther; 2021 Jan; 12(1):301-312. PubMed ID: 33249545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism.
    Hu X; Liu W; Yan Y; Liu H; Huang Q; Xiao Y; Gong Z; Du J
    Eur J Pharmacol; 2019 Feb; 845():91-98. PubMed ID: 30287151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studying the Roles of the Renin-Angiotensin System in Accelerating the Disease of High-Fat-Diet-Induced Diabetic Nephropathy in a db/db and ACE2 Double-Gene-Knockout Mouse Model.
    Chen CY; Lin MW; Xie XY; Lin CH; Yang CW; Wu PC; Liu DH; Wu CJ; Lin CS
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Susceptibility Genes in Diabetic Nephropathy.
    Wei L; Xiao Y; Li L; Xiong X; Han Y; Zhu X; Sun L
    Kidney Dis (Basel); 2018 Nov; 4(4):226-237. PubMed ID: 30574499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Narrative Review of New Treatment Options for Diabetic Nephropathy.
    Pillai A; Fulmali D
    Cureus; 2023 Jan; 15(1):e33235. PubMed ID: 36733548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut microbiota microbial metabolites in diabetic nephropathy patients: far to go.
    Yu JX; Chen X; Zang SG; Chen X; Wu YY; Wu LP; Xuan SH
    Front Cell Infect Microbiol; 2024; 14():1359432. PubMed ID: 38779567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.